Cytosorbents Corporation (NASDAQ: CTSO) Stock Information | RedChip

Cytosorbents Corporation (NASDAQ: CTSO)


$0.8749
+0.0365 ( +0.56% ) 74.5K

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Market Data


Open


$0.8749

Previous close


$0.8384

Volume


74.5K

Market cap


$47.81M

Day range


$0.8360 - $0.9020

52 week range


$0.7000 - $1.8200

SEC Filings


Form Type Description Pages Date
8-k 8K-related 18 Dec 13, 2023
8-k 8K-related 15 Dec 11, 2023

Latest News